Pemetrexed + AVELUMAB for carcinoma, transitional cell

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 16 Nov 2018: Trial registered, NCT03744793
  2. 11 Apr 2019: Trial started, NCT03744793

The trials

NCT03744793: Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer

State
Under way
Phase
Phase 2
People
18 taking part
Started
11 Apr 2019
Primary completion
31 Jan 2027
Arms
Treatment (pemetrexed, avelumab)
Results
None posted
  1. 16 Nov 2018: Trial registered
  2. 11 Apr 2019: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.